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AbstrACt
Introduction Poor health of sex workers continues to be 
a source of international concern. Sex work is frequently 
linked with problematic drug use and drug-dependent 
sex workers typically work on the street, experiencing 
the greatest risks to health compared with the general 
population. Street sex workers (SSWs) are much more 
likely to have experienced incidences of physical and 
sexual assault, increasing their risk of developing post-
traumatic stress disorder (PTSD). We have developed 
a novel complex intervention designed to reduce 
illicit drug use in drug-dependent female SSWs which 
involves: female SSW drug treatment groups (provided 
by a specialist charity) in a female SSW setting (female 
sex worker charity premises) provided by female-only 
staff, PTSD care with eye movement desensitisation and 
reprocessing (EMDR) therapy provided by female staff 
from National Health Service (NHS) mental health services.
Methods and analysis A mixed methods study 
investigating the feasibility and acceptability of this 
intervention to inform the design of a future randomised 
controlled trial. The study aims to recruit up to 30 
participants from November 2017 to March 2018 at 
a single site, with the intervention being delivered 
until December 2018. It will gather quantitative data 
using questionnaires and group attendance. Drug 
treatment group observations and in-depth interviews 
undertaken with up to 20 service users and 15 service 
providers to examine experiences and acceptability of 
the intervention. Study feasibility will be assessed by 
evaluating the recruitment and retention of participants 
to the intervention; the feasibility of NHS and third sector 
organisations working closely to coordinate care for a SSW 
population; the potential for specialist NHS mental health 
services to screen and provide EMDR therapy for drug-
dependent SSWs and potential costs of implementing the 
intervention.
Ethics and dissemination This study was approved by 
South West–Frenchay Research Ethics Committee (REC 
reference: 17/SW/0033; IRAS ID: 220631) and the Health 
Research Authority (HRA). Findings will be disseminated 
through research conferences and peer-reviewed journals.
IntroduCtIon
Sex workers are internationally recognised as 
a group who experience poor health.1 2 Sex 
work and drug use are frequently linked,3–5 
and previous research has shown that street sex 
workers (SSWs) experience worse health than 
sex workers in off-street settings6 and use heroin 
and crack cocaine as their main drugs of depen-
dency.7 Dependency on illicit drugs underpins 
their excess morbidity,7 8 drives risk-taking 
while selling sex,9 10 as well as the direct and 
indirect health risks of injection drug use.11 12 
Furthermore, illicit drug dependency can keep 
women entrenched in sex work as ceasing sex 
strengths and limitations of this study
 ► This is a mixed methods study to investigate the 
feasibility and acceptability of a novel intervention 
designed to reduce levels of post-traumatic stress 
disorder in order to support a reduction in illicit drug 
use in female drug-dependent street sex workers 
(SSWs).
 ► The complex intervention addresses issues high-
lighted by female SSWs in previous qualitative work 
as well as quantitative systematic review evidence.
 ► The involvement of service users and a range of 
multidisciplinary service providers has been crucial 
in the development and design of the proposed in-
tervention and study.
 ► Conclusions about effectiveness or efficacy of the 
intervention are not possible due to the study being 
a single-arm feasibility study; however, this study 
will enable the refinement of the intervention for a 
future effectiveness trial.
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work is inversely related to levels of injection drug use13 and 
drug-dependent SSWs describe being trapped in a work-
score-use cycle.14 
Despite these significant drug treatment needs, drug-de-
pendent SSWs have poorer outcomes from drug treatment 
services compared with other service users.15 16 Previous 
SSW-focused interventions aiming to reduce levels of 
drug use have focused on heroin and/or crack cocaine 
and employed educational approaches,9 17 substitute 
prescribing-based18 19 and psychological approaches 
including motivational interviewing20 but none convinc-
ingly demonstrated a positive effect in reducing drug 
use.21 While the challenges of mixed-gender drug treat-
ment services contribute to the lack of effectiveness22 23 
and cost-effectiveness for female service users in partic-
ular,24 female SSWs have been found to face additional 
obstacles in mixed-gender groups related to their sex 
work history.25 For example, feelings of stigmatisation 
from other male and female service users following 
disclosure of sex work and adverse interactions with previ-
ously known male service users potentially prevent SSWs 
from discussing unresolved trauma, undermining their 
engagement in treatment.
High levels of poor mental health, a significant problem 
among SSWs,26 27 have previously been highlighted as 
contributing to poor drug treatment outcomes.28 Expe-
rience of abuse and violence, common among SSWs,29 30 
has led to recommendations for female-only trauma-fo-
cused drug treatment interventions31 and there is some 
evidence that certain subgroups, such as SSWs,32 may 
benefit from a trauma-focused approach. A recent 
Cochrane review of treatment of comorbid post-trau-
matic stress disorder (PTSD) and drug dependency33 
suggested that individual trauma-focused therapy along-
side drug treatment appeared to have best outcomes 
for PTSD and reducing levels of drug use in the longer 
term. However, groups with severe and complex presen-
tations were excluded from most included studies and, 
to date, there is no robust evidence of the impact of an 
integrated treatment approach in female drug-depen-
dent SSWs.
dEvElopMEnt of thE IntErvEntIon
A novel intervention addressing the unique and complex 
needs of female drug-dependent SSWs was developed 
in collaboration with service providers and informed 
by existing research. It was designed to occur prior to 
typical ‘mainstream’ drug treatment interventions (for 
both male and female drug-dependent individuals) and 
proposes an integrated care pathway through an innova-
tive multiagency partnership. This pathway includes:
1. Female SSW-only groups in an SSW-only environment 
facilitated by female members of local drug treatment 
services.
2. Screening for PTSD by female staff from local specialist 
National Health Service (NHS) mental health services.
3. One-to-one PTSD therapy (eye movement desensiti-
sation and reprocessing (EMDR)) with a female NHS 
clinician working within a specialist trauma service.
Addressing sex working history during initial drug 
treatment groups as well as screening and treating under-
lying PTSD is designed to prepare SSWs to engage more 
effectively with mainstream drug services with the aim 
of achieving better long-term health outcomes. EMDR 
was selected as it is a recommended first-line treatment 
for PTSD in UK National Institute of Health and Care 
Excellence (NICE) guidelines,34 and unlike cognitive 
behavioural therapy, it does not require homework which 
may be a challenge for drug-dependent SSW and can be 
a relatively short course of treatment (NICE guidelines 
recommend up to 12 sessions).34 EMDR is a form of 
psychotherapy which uses eye movements or other forms 
of bilateral stimulation and has similarities with slow-wave 
sleep and its role in memory consolidation35 to purport-
edly assist clients in processing distressing memories 
and beliefs.36 The use of EMDR in this population is a 
novel approach and understanding of its use in terms of 
acceptability in drug-dependent participants, including 
opioid substitution treatment (OST) is limited.
Aims
This feasibility study will address the unanswered inter-
vention questions required for a future large-scale 
randomised controlled trial to determine the effective-
ness and cost-effectiveness of a complex intervention to 
reduce levels of PTSD in order to support a reduction 
in illicit drug use in female drug-dependent SSWs. The 
specific feasibility study objectives are to:
 ► Evaluate the recruitment and retention of partici-
pants to the intervention.
 ► Investigate the feasibility of three services of differing 
statutory and non-statutory, clinical and non-clinical 
backgrounds working closely to provide a complex 
intervention for drug-dependent female SSWs.
 ► Examine the experience and acceptability of the 
intervention for SSWs and service providers.
 ► Explore costs associated with the intervention.
MEthods And AnAlysIs
study design
The study uses a single-site mixed methods approach 
to investigate the feasibility and acceptability of a novel 
complex intervention designed to reduce levels of PTSD 
in order to support a reduction in illicit drug use in 
female-drug dependent SSWs. The protocol was written 
in accordance with the Standard Protocol Items: Recom-
mendations for Interventional Trials guidelines.37 The 
study aims to recruit up to 30 participants from November 
2017 to March 2018, with the intervention being deliv-
ered until December 2018.
study setting
The study will take place in an inner city setting in a large 
UK city. Recruitment, drug group sessions and PTSD 
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assessment will take place in a female-only sex worker 
charity’s drop-in support service, where advice, health 
and general day-to-day support are provided.
Inclusion and exclusion criteria
Participants are eligible for the study if they are female 
aged 18 years or older, sold sex on the street in the UK at 
least once a week in the last calendar month (or 3 out of 
the 4 previous weeks) and have used heroin and or crack 
cocaine at least once a week in the last calendar month 
(or 3 out of the 4 previous weeks).
Participants are excluded from the study if they do not 
identify as female gender, are under 18 and have not sold 
sex on the street in the UK and not used heroin or crack 
cocaine at least once a week in the last calendar month.
participant recruitment
Study promotional flyers will be left in organisations and 
services that SSWs are known to use, such as a SSW charity 
outreach van and drop-in support service, housing organ-
isations, specialist drug and alcohol services. SSWs can 
make direct contact with the researcher via telephone 
(with an answerphone facility) or ask support staff to 
phone on their behalf. Researchers will also attend the 
SSWs drop-in support service to directly approach poten-
tial participants with a promotional flyer, as proposed by 
the SSW patient and public involvement (PPI) consulta-
tion group who recommended this as the best arrange-
ment for them. Participants will also be recruited by 
word-of-mouth through SSWs who are aware of the study 
and have contacts who may want to take part (ie, via snow-
ball sampling).
The researcher will conduct eligibility screening 
according to the inclusion/exclusion criteria either face-
to-face or over the telephone. Participants meeting the 
inclusion criteria will be invited to provide fully informed, 
written consent to participate in the study at the time of 
screening if that is face-to-face, or at a meeting arranged 
after telephone screening. Baseline assessment will be 
completed for all consenting participants and includes 
self-report measures of illicit drug use, sex work frequency 
and PTSD symptoms experienced (see Data collection 
methods section). A preferred communication and study 
contact strategy will be agreed with each individual at the 
outset of their participation. For participants not meeting 
the inclusion criteria, screening data will remain anony-
mised for eligibility reporting purposes only.
the intervention pathway
It is recognised that participant progression through the 
intervention is unlikely to be linear and that group alloca-
tion and reallocation will be sensitive to the needs of indi-
viduals and other group members. All service provider 
partners will participate in monitoring how individuals 
and the wider group(s) are responding to the various 
aspects of the intervention; for example, we may find 
that women respond well to female, sex worker-only drug 
groups and develop stability behaviour more quickly than 
expected, in which case, we may move them through the 
intervention quicker. We expect the intervention to take 
approximately 23 weeks or 6 months. Individual partici-
pants will be supported on a case-by-case basis which will 
be dependent on their drug use, treatment and engage-
ment with services. Figure 1 details the most linear route 
possible through the intervention.
‘Getting started’ drug treatment group
The group will take place in a female sex worker charity 
premises with a maximum of eight places. The aim of 
the ‘Getting started’ group is to enable participants to 
achieve a level of stability, to reduce fear and anxiety about 
engaging in a group setting, to get used to the format 
and level of disclosure expected, to explore what skills are 
needed to engage in a group, to experience the feelings 
people are left with after a group and to learn how to 
manage these. During the group facilitation, topics that 
will be routinely and regularly covered are maintaining 
boundaries, why a group setting is used, personal resil-
ience/strengths and setting SMART (specific, measur-
able, achievable, relevant and time bound) goals. After 
attending four group meetings, if participants are 
perceived by the group facilitators as exhibiting evidence 
of life/drug use stability such as engagement and func-
tioning in the group, positive interaction with group facil-
itators, regular OST, they will be offered transfer to the 
‘Preparation for Recovery’ group. The group will be an 
open group and participants may attend irregularly, but 
regular attendance will be encouraged via weekly phone 
text message reminders. Those participants who are 
injecting opiates (heroin) and are not currently receiving 
OST will be encouraged to access an OST prescription 
and be signposted to local services.
‘Preparation for recovery’ drug treatment group
The group will take place in a female sex worker charity 
premises, and there will be a maximum of eight places. 
The aim of the ‘Preparation for recovery’ group is to focus 
participants on building relationships and connections in 
the group, looking at peoples’ barriers to motivation for 
change, weighing up pros and cons of drug use, exploring 
triggers for using, helping people to manage difficult feel-
ings and looking at support networks. This part of the 
programme mimics mainstream drug services and aims 
to prepare women for joining mixed-gender groups. The 
group consists of a rolling programme of eight sessions to 
support participants to continue managing drug use and 
use of an OST prescription.
Participants who attend three consecutive ‘Preparation 
for Recovery’ groups and are assessed by group facili-
tators to be achieving drug stabilisation will be offered 
screening for PTSD. Participants found to be currently 
experiencing PTSD symptoms will be offered inclusion 
in the ‘Stabilisation’ group in preparation for receiving 
treatment for their PTSD symptoms while continuing to 
attend the ‘Preparation for Recovery’ group. If a partic-
ipant is found not to be experiencing PTSD symptoms, 
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they will continue in the ‘Preparation for Recovery’ group 
for the usual duration of the group (6–8 weeks) or until 
a group facilitator feels they are ready to be referred on 
to mainstream drug services. The group will be an open 
group and participants may attend irregularly, but regular 
attendance will be encouraged via phone text message 
reminders. If a participant is considered to no longer be 
achieving stability, they will be reassigned to the ‘Getting 
started’ group until they begin to stabilise once more.
Screening for PTSD
Participants will be individually screened for currently 
experiencing PTSD symptoms in a 90 min one-to-one 
session with a registered female clinical psychologist. The 
session will consist of a clinical interview to elicit informa-
tion about symptoms related to the diagnostic criteria for 
PTSD as stated in the American Psychiatric Association’s 
Diagnostic and Statistical Manual of Mental Disorders 
5 (DSM-5).38 The PTSD Check List-5 (PCL-5) is used to 
assist the clinical assessment, provide a baseline score and 
provide the clinical psychologist with a provisional PTSD 
diagnosis. If the participant is found to be currently expe-
riencing PTSD symptoms, she will be offered a place in 
the ‘Stabilisation’ group. If she is deemed to not benefit 
from the ‘Stabilisation’ group, she can continue in the 
‘Preparation for recovery’ group with eventual referral to 
mainstream drug services (see above).
Figure 1 DUSSK study participant flow diagram. 
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PTSD ‘Stabilisation’ group
The ‘Stabilisation’ group will be a rolling programme of 
five, 2-hour sessions to be held in a clinical setting. The 
aim of the group is to equip participants with the neces-
sary skills to self-soothe and reorientate in preparation for 
the one-to-one EMDR treatment. The group will be facil-
itated by a female clinical psychologist. It is anticipated 
that the optimum size for the ‘Stabilisation’ group will 
be 3 to 12, and once all sessions have been completed, 
participants will be eligible to progress to one-to-one 
PTSD treatment. If participants fail to attend two consec-
utive sessions, they will be considered to have withdrawn 
from treatment.
Treatment for PTSD
Treatment will occur in a clinical setting, for example, 
existing mental health service locations or local general 
practitioner (GP) practice private room. Participants 
will receive up to 12 one-to-one EMDR sessions for 
90 min with a female clinical psychologist on a weekly, 
or fortnightly, basis. This treatment will aim to target 
the most distressing memories and process the dysfunc-
tional information in order to reduce distress related to 
that memory and diminish the symptoms of PTSD expe-
rienced by participants. Aiming to improve self-esteem 
and self-efficacy, the treatment should enable the partic-
ipant to better tolerate the residue of difficult experi-
ences, reducing the need to self-medicate their distress 
with drugs and alcohol. If a participant is not suffi-
ciently stabilised or too intoxicated due to recent drug 
or alcohol use, therapy will be deferred to a mutually 
agreed time and date. If participants continue to attend 
too intoxicated for treatment on two occasions, they will 
be discharged from EMDR treatment but can continue 
to attend ‘Preparation for recovery’ group sessions. If 
during treatment participants are assessed as experi-
encing acute symptoms that require further support 
from mental health services, the on-call crisis team will 
be contacted to arrange care. Participants’ case workers 
will also be informed of the referral as part of ongoing 
support arrangements. Participants may attend EMDR 
sessions irregularly, but if they do not attend two consec-
utive appointments, they will be considered to have 
withdrawn from treatment. Regular attendance will be 
encouraged by reminders to attend appointments via 
text message, letter and case worker.
The participant will be encouraged to continue to be 
supported by the ‘Preparation for Recovery’ group during 
trauma screening, stabilisation group and one-to-one 
sessions. Women are able to see a clinical psychologist or 
request further assistance from mental health services in 
line with routine practice if required. Once the partici-
pant is assessed as having completed PTSD treatment, 
they will be referred by the ‘Preparation for Recovery’ 
group facilitators to attend mainstream drug services, 
to access ongoing support and treatment appropriate to 
their stage of recovery.
Sample size
As this is a feasibility study, there is no formal sample size 
calculation. We aim to recruit up to 30 participants to fully 
evaluate the intervention processes and this is consid-
ered a large enough sample to estimate the proportion 
of eligible people who are willing to participate, attrition 
rate and consider the practicalities of recruitment and 
delivering the intervention.
data collection methods
Baseline data collection
Baseline data will be collected by researchers at the time 
of recruitment once participant consent procedures are 
complete. Baseline data collected will be related to self-re-
port of levels of illicit drug use, involvement in street 
sex work, completion of PCL-539 (a 20-item self-report 
measure that assesses the 20 DSM-5 symptoms of PTSD) 
and demographics (age, ethnicity).
Process evaluation
Once recruited, attendance at and movement through 
the intervention will be monitored and recorded. 
Number of participants fully and partially completing the 
intervention pathway and patterns of attendance will be 
monitored weekly. An attendance register will be taken at 
the start of each of the groups by the group facilitators. 
Cost assessments in the feasibility study will be explor-
atory and informed by the qualitative interviews and 
service provider estimates for staff time and accommoda-
tion costs. These measures will also enable the assessment 
of the fidelity of the intervention as a whole against the 
proposed intervention pathway.
Qualitative study
To examine participant and service provider views and 
experiences of the intervention, we will conduct obser-
vations (of the ‘Getting started’ and ‘Preparation for 
Recovery’ groups) to understand delivery, provide context 
and observe interactions and dynamics and undertake 
in-depth semistructured qualitative interviews to explore 
how the intervention could be made more acceptable 
and feasible. Qualitative findings will help to illuminate 
the strengths and weaknesses of the intervention and 
refine its final format.
With participants’ verbal consent, a qualitative 
researcher will undertake up to 8 hours of non-par-
ticipant observations to understand how the ‘Getting 
started’ and ‘Preparation for Recovery’ groups are oper-
ationalised and delivered in day-to-day practice. Any 
group member can ask the researcher to leave the group 
for any reason. If at any time the researcher’s presence 
is considered by facilitators to be disrupting the group 
dynamics, they will leave the room. The researcher will 
write accounts of observations based on brief notes taken 
directly after the groups.40 These field notes may include 
both direct observations and reflection on what has been 
observed. Observations will record activities, interactions 
and communication patterns.
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All study participants will be asked at the time of study 
consent if they are willing to subsequently be contacted 
about taking part in a qualitative interview. A purpo-
sive sample of those agreeing to be interviewed will be 
drawn in relation to variables such as age, frequency 
of drug use and sex work behaviour (using baseline 
questionnaire data) and levels of engagement with the 
intervention (using attendance data). Use of purposive 
sampling will aim to select interview participants that 
provide maximum variation in views and experiences. 
Interviews will be conducted face-to-face and written 
informed consent will be taken before starting the inter-
view. Interview participants will be given a £20 high street 
shopping voucher as a thank you for their time. Partici-
pant interviews will be conducted with (1) service users 
that complete the ‘Getting started’ and ‘Preparation for 
Recovery’ groups and are not diagnosed with PTSD, (2) 
service users that complete the ‘Stabilisation’ group and 
treatment for complex PTSD and (3) service users that 
withdrew from any of the treatment groups. These inter-
views will consider and compare service user and service 
provider views, experiences, acceptability and costs of the 
intervention and suggested modifications to the interven-
tion and study design. SSW interviews will explore initial 
impressions of the intervention, views on the recruitment 
strategy, factors influencing intervention attendance 
and experiences of the intervention including perceived 
benefits.
Service provider interviews will be conducted 
towards the end of the study. In addition to the topics 
above, these interviews will seek to understand opera-
tional issues of running the intervention, interagency 
working and general perspectives on delivering the 
intervention.
The sample sizes will be determined by the need to 
achieve data saturation, such that no new themes are 
emerging from the data by the end of data collection.41 
Interviews will be analysed in batches, and sampling 
will continue until no new themes are emerging from 
the interviews. The sample size of up to 20 service users 
and up to 15 service providers is expected to be suffi-
cient to achieve this aim. With informed consent from 
participants, interviews will be recorded using a digital 
voice recorder, transcribed and anonymised to protect 
confidentiality.
data analysis
Statistical analysis
All statistical analyses will be carried out according to 
the study analysis plan. The analysis plan details that 
we will conduct descriptive analyses using means, SD 
and non-parametric measures (where appropriate) to 
describe the characteristics of the participants and to 
analyse the feasibility and study process data. These will 
include but will not be limited to the number of partic-
ipants approached to participate and their recruitment 
and retention, the number of participants partially and 
fully completing the intervention at each stage and 
participant patterns of attendance. Resource use data 
collected on staff time and accommodation use will be 
multiplied by relevant unit cost data to generate a basic 
cost associated with provision of the intervention.
Qualitative analysis
For the observations, the researcher will write detailed 
anonymised field notes, which will be transcribed for anal-
ysis. Interview audio files will be fully transcribed, anony-
mised and checked for accuracy. Observation field notes 
and interview transcripts will be imported into NVivo V.10 
qualitative data analysis software to aid data management. 
Analysis will begin shortly after data collection starts and 
will be ongoing and iterative. Analysis will inform further 
data collection: for instance, analytic insights from data 
gathered in earlier interviews will help identify any changes 
that need to be made to the interview topic guide for use 
during later interviews. Thematic analysis,42 using a data-
driven inductive approach,43 will be used to scrutinise the 
data in order to identify and analyse patterns and themes 
of particular salience for participants and across the 
data set using constant comparison techniques.44 45 One 
researcher will lead the analysis, but other team members 
will independently code a subsample of transcripts, and 
all will meet to discuss the preliminary coding framework 
and themes, to ensure that the emerging analysis is trust-
worthy and credible and to maximise rigour.
patient and public involvement
Intervention and study design was developed based on 
input from the study PPI group that included women 
currently and previously involved in SSW and illicit drug 
use. The group convened before and during set up, 
contributed to the protocol development as well as the 
design of participant facing study documentation. Subse-
quent meetings have informed recruitment, topic guides, 
plain language study summary and plans for study dissem-
ination. Ongoing PPI meetings will focus on trouble-
shooting issues identified during the study process and at 
the end of the study will focus on interpretation of results 
and dissemination methods.
EthICs And dIssEMInAtIon
Ethical approval for the drug use in street sex workers 
DUSSK) study has been received.
summary of consent procedures
Eligible participants will provide fully informed, written 
consent to participate in the study at the time of screening 
and, if they are willing, consent to be contacted at a point 
later during the study about a subsequent qualitative 
interview. Written informed consent will be provided 
before starting the recorded qualitative interviews with 
participants and service providers. Qualitative researchers 
will observe treatment groups after obtaining the partici-
pants’ verbal consent.
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Adverse events
Adverse events (AEs) and standardised operating proce-
dures have been developed and will be followed by all 
researchers and service providers working on the study. 
Any unexpected AE defined as any untoward medical 
occurrence in a study participant to whom an inter-
vention has been administered and serious AE (SAE) 
(defined below) will be reported by the researchers and 
service providers to the principal investigator who will 
keep records of each event to be monitored and reviewed 
at monthly Project Management Group meetings.
The principal investigator (NJ, a consultant in sexual 
health), study collaborator/designer (JM, a Professor, GP 
and expert in drug dependence and sex worker health 
inequality) and study coordinator (NMR) will assess the 
nature of reported AEs and SAEs for seriousness, causality 
and expectedness. Following the initial report, follow-up 
data may be requested by the study coordinator. All SAEs 
assessed to be related to the intervention and unexpected 
will be reported to the main Research Ethics Committee, 
Health Research Authority, the Sponsor and its research 
governance office, within 15 days of receiving notification 
of the SAE. If the individual affected is considered to be at 
ongoing risk, their caseworker will be informed.
SAE definition
The definition of a SAE is any untoward and unexpected 
medical occurrence or effect in a study participant that 
is related to the intervention which: results in death; is 
life-threatening (refers to an event during which the 
participant was at risk of death at the time of the event, it 
does not refer to an event which might have caused death 
had it been more severe in nature); requires hospitalisa-
tion, or prolongation of existing hospitalisation; results in 
persistent or significant disability or incapacity or is other-
wise considered medically significant by the investigator.
study sponsorship
The University of Bristol is the Sponsor for the study. 
Delegated responsibilities will be assigned to the Univer-
sity and NHS trusts taking part in this study. Collabora-
tion for Leadership in Applied Health Research and Care 
(CLAHRC) West is responsible for, and administer, the 
financial aspects of the study. The study is open to inspec-
tion and audit by the University of Bristol under its remit as 
Sponsor.
dissemination
The study findings will be disseminated through publica-
tion in peer-reviewed open access journals as well as presen-
tation at local and national conferences. We will make 
commissioners aware of our findings through meetings 
and circulation of appropriate materials highlighting the 
results. We will also ensure study participants, and members 
of the research population more widely, are aware of the 
findings through flyers and presentations. We will involve 
service users and our PPI group in all stages of dissemina-
tion and encourage them to copresent and contribute if 
they feel that is appropriate.
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